Interaction of Sp. RIT 592 Induces the Production of Broad-spectrum Antibiotics in Sp. RIT 594

Overview

Journal Front Pharmacol

Date 2024 Aug 16

PMID 39148551

Authors

Anutthaman Parthasarathy

Renata Rezende Miranda

T J Bedore

Lizabeth M Watts

Pavan K Mantravadi

Narayan H Wong

Jonathan Chu

Joseph A Adjei

Amisha P Rana

Michael A Savka

Zackery P Bulman

Eli J Borrego

Andre O Hudson

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance (AMR) is one of the most alarming global public health challenges of the 21st century. Over 3 million antimicrobial-resistant infections occur in the United States annually, with nearly 50,000 cases being fatal. Innovations in drug discovery methods and platforms are crucial to identify novel antibiotics to combat AMR. We present the isolation and characterization of potentially novel antibiotic lead compounds produced by the cross-feeding of two rhizosphere bacteria, sp. RIT 592 and sp. RIT 594. We used solid-phase extraction (SPE) followed by liquid chromatography (LC) to enrich antibiotic extracts and subsequently mass spectrometry (MS) analysis of collected fractions for compound structure identification and characterization. The MS data were processed through the Global Natural Product Social Molecular Networking (GNPS) database. The supernatant from RIT 592 induced RIT 594 to produce a cocktail of antimicrobial compounds active against Gram-positive and negative bacteria. The GNPS analysis indicated compounds with known antimicrobial activity in the bioactive samples, including oligopeptides and their derivatives. This work emphasizes the utility of microbial community-based platforms to discover novel clinically relevant secondary metabolites. Future work includes further structural characterization and antibiotic activity evaluation of the individual compounds against pathogenic multidrug-resistant (MDR) bacteria.

References

Smanski M, Schlatter D, Kinkel L . Leveraging ecological theory to guide natural product discovery. J Ind Microbiol Biotechnol. 2015; 43(2-3):115-28. DOI: 10.1007/s10295-015-1683-9. View

Coates A, Hu Y, Bax R, Page C . The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002; 1(11):895-910. DOI: 10.1038/nrd940. View

Van Moll L, De Smet J, Cos P, Van Campenhout L . Microbial symbionts of insects as a source of new antimicrobials: a review. Crit Rev Microbiol. 2021; 47(5):562-579. DOI: 10.1080/1040841X.2021.1907302. View

Tedesco P, Palma Esposito F, Masino A, Vitale G, Tortorella E, Poli A . Isolation and Characterization of Strain sp. KRL4, a Producer of Bioactive Secondary Metabolites from a Tibetan Glacier. Microorganisms. 2021; 9(5). PMC: 8143284. DOI: 10.3390/microorganisms9050890. View

Minogue T, Daligault H, Davenport K, Bishop-Lilly K, Broomall S, Bruce D . Complete Genome Assembly of Escherichia coli ATCC 25922, a Serotype O6 Reference Strain. Genome Announc. 2014; 2(5). PMC: 4175212. DOI: 10.1128/genomeA.00969-14. View

Ventola C . The antibiotic resistance crisis: part 2: management strategies and new agents. P T. 2015; 40(5):344-52. PMC: 4422635. View

Kar J, Ramrao D, Zomuansangi R, Lalbiaktluangi C, Singh S, Joshi N . Revisiting the role of cyanobacteria-derived metabolites as antimicrobial agent: A 21st century perspective. Front Microbiol. 2022; 13:1034471. PMC: 9717611. DOI: 10.3389/fmicb.2022.1034471. View

Sur S, Romo T, Grossfield A . Selectivity and Mechanism of Fengycin, an Antimicrobial Lipopeptide, from Molecular Dynamics. J Phys Chem B. 2018; 122(8):2219-2226. PMC: 5832627. DOI: 10.1021/acs.jpcb.7b11889. View

Bulman Z, Wicha S, Nielsen E, Lenhard J, Nation R, Theuretzbacher U . Research priorities towards precision antibiotic therapy to improve patient care. Lancet Microbe. 2022; 3(10):e795-e802. DOI: 10.1016/S2666-5247(22)00121-5. View

10.

Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee S . antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic Acids Res. 2019; 47(W1):W81-W87. PMC: 6602434. DOI: 10.1093/nar/gkz310. View

11.

Scherlach K, Hertweck C . Mining and unearthing hidden biosynthetic potential. Nat Commun. 2021; 12(1):3864. PMC: 8222398. DOI: 10.1038/s41467-021-24133-5. View

12.

Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M . Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 2012; 41(1):e1. PMC: 3592464. DOI: 10.1093/nar/gks808. View

13.

Lee H, Lee K . Cathepsin B inhibitory peptides derived from beta-casein. Peptides. 2000; 21(6):807-9. DOI: 10.1016/s0196-9781(00)00212-6. View

14.

Klein V, Bray W, Wang H, Edmondson Q, Schwochert J, Ono S . Identifying the Cellular Target of Cordyheptapeptide A and Synthetic Derivatives. ACS Chem Biol. 2021; 16(8):1354-1364. PMC: 8545353. DOI: 10.1021/acschembio.1c00094. View

15.

Huang Y, Sokolowski K, Rana A, Singh N, Wang J, Chen K . Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing . Antimicrob Agents Chemother. 2021; 65(9):e0069221. PMC: 8370209. DOI: 10.1128/AAC.00692-21. View

16.

Jaki B, Zerbe O, Heilmann J, Sticher O . Two novel cyclic peptides with antifungal activity from the cyanobacterium Tolypothrix byssoidea (EAWAG 195). J Nat Prod. 2001; 64(2):154-8. DOI: 10.1021/np000297e. View

17.

Bulman Z, Satlin M, Chen L, Kreiswirth B, Shin B, Walsh T . New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365650. DOI: 10.1128/AAC.02023-16. View

18.

Lau R, Rinehart K . Berninamycins B, C, and D, minor metabolites from Streptomyces bernensis. J Antibiot (Tokyo). 1994; 47(12):1466-72. DOI: 10.7164/antibiotics.47.1466. View

19.

Planet P . Life After USA300: The Rise and Fall of a Superbug. J Infect Dis. 2017; 215(suppl_1):S71-S77. PMC: 5853207. DOI: 10.1093/infdis/jiw444. View

20.

Tyc O, de Jager V, van den Berg M, Gerards S, Janssens T, Zaagman N . Exploring bacterial interspecific interactions for discovery of novel antimicrobial compounds. Microb Biotechnol. 2017; 10(4):910-925. PMC: 5481530. DOI: 10.1111/1751-7915.12735. View